Weekly Update #246: More IPO Updates

EquityZen has produced these weekly updates for secondary investors, shareholders and company representatives.

If you find this useful, subscribe to our weekly newsletter!

Weekly Update

Live offerings, preview listings, and some analysis on the pre-IPO space

In order to view EquityZen's Investment Offerings, you must be an Accredited Investor.

Verify your Accredited Investor status

Hello Investors,

More IPO updates this week…

With the flurry of S-1 activity YTD, we now count 8 VC backed companies that have/are slated to IPO. This includes Docusign, Carbon Black (just filed!), Zuora, Pivotal, Smartsheet as well as those that have already listed -- Spotify (SPOT), Zscaler (ZS), and Dropbox (DBX). Valuations have generally held up so far, despite some underlying market volatility. Dropbox did experience an IPO “down round”, which we believe was likely driven by a stretched valuation in its last funding round (DBX last took money from VC investors in 2014, a year generally characterized generally by ebullience in private valuations).

Other key updates include:

> Zuora increased its pricing range to $11 to $13, from $9 to $11. We estimate this translates to a 7-8x multiple on forward revenue, above the SaaS average.

> As expected, e-signature company Docusign (expected ticker “DOCU”) filed an amended S-1 last week, with additional disclosure on TTM (trailing twelve month) results. The company’s timing and expected pricing are still TBA. Overall, we believe the market will likely welcome DOCU’s strong market position and opportunity as well as its balanced growth profile. Some quick notes on the filing are included below:

Revenue metrics remain solid, with TTM sales at $519M, up 36% year-over-year. Total customers grew ~30% over this time frame. DOCU has estimated the size of the e-signature market at $25B, suggesting ample growth opportunities ahead. Note that competition could eat into this opportunity somewhat -- key competitors for DOCU include large, deep-pocketed players like Adobe and other startups, e.g. HelloSign.

Docusign Annual Revenue Growth (Fiscal 2018, 2017)

Source: Company filings and EquityZen Securities

- Strong dollar-based net retention should support healthy growth going forward. DOCU’s dollar-based expansion rate remains well above 100%, suggesting the company continues to expand business with existing customers. Growing with existing customers often carries favorable economics compared to attracting new business.

Docusign Dollar-Based Net Retention

Source: Company filings and EquityZen Securities

- Importantly, Docusign seems to have done an admirable job balancing growth with profitability. DOCU’s operating margins exceed other SaaS peers in their quarters leading up to IPO, steadily climbing to just-shy-of-positive as of the company’s last fiscal quarter. Part of the profitability improvement is attributable to above-average gross margins. DOCU also runs leaner on G&A and R&D relative to its peers. Low R&D can sometimes signal underinvestment; however, it is important to remember that (a) SaaS peers compete in different underlying sectors which can have an impact on required R&D and (b) DOCU may now be reaping some dividends from past expenditures as a leading player in the e-signature market.     

Docusign Operating Margins; 7 Quarters Leading Up to IPO

Source: Company filings and EquityZen Securities

Docusign Gross Margins; 7 Quarters Leading Up to IPO

Source: Company filings and EquityZen Securities

Docusign R&D to Revenue; 7 Quarters Leading Up to IPO

Source: Company filings and EquityZen Securities

Docusign G&A to Revenue; 7 Quarters Leading Up to IPO

Source: Company filings and EquityZen Securities

 

Other items we are reading this week:

Thanks,
Catherine Klinchuch
Finance & Research Lead, EquityZen

 

Funding Rounds Since Last Week

Invest in Instacart
Instacart - Instacart raises another $150 million
Invest in RefleXion Medical
RefleXion Medical - RefleXion Medical Raises $100 Million Series C to Commercialize Revolutionary Cancer Treatment
Invest in Welltok
Welltok - Welltok Raises $75M in Funding
Invest in Symphony
Symphony - Symphony Communications raises $67 mln as it eyes IPO
Invest in BetterCloud
BetterCloud - BetterCloud Closes $60M Funding Round
Invest in Arvinas
Arvinas - Arvinas Completes $55M Series C Financing
Invest in Magenta Therapeutics
Magenta Therapeutics - Magenta Therapeutics Secures $52M in Series C Financing
Invest in WorkFusion
WorkFusion - WorkFusion Raises $50 Million Series E to Bring AI-powered Software Robots to Enterprise Business
Invest in Formlabs
Formlabs - Formlabs Pulls In $30M to Push Line of 3D Printers

Have questions?